background
specif
antivir
drug
proven
effect
treatment
patient
sever
coronaviru
diseas
remdesivir
nucleosid
analogu
prodrug
inhibitori
effect
pathogen
anim
human
coronavirus
includ
sever
acut
respiratori
syndrom
coronaviru
vitro
inhibit
middl
east
respiratori
syndrom
coronaviru
replic
anim
model
randomis
doubleblind
placebocontrol
multicentr
trial
ten
hospit
hubei
china
elig
patient
adult
age
year
admit
hospit
laboratoryconfirm
infect
interv
symptom
onset
enrol
day
less
oxygen
satur
less
room
air
ratio
arteri
oxygen
partial
pressur
fraction
inspir
oxygen
mm
hg
less
radiolog
confirm
pneumonia
patient
randomli
assign
ratio
intraven
remdesivir
mg
day
follow
mg
day
singl
daili
infus
volum
placebo
infus
day
patient
permit
concomit
use
lopinavirritonavir
interferon
corticosteroid
primari
endpoint
time
clinic
improv
day
defin
time
day
randomis
point
declin
two
level
sixpoint
ordin
scale
clinic
statu
discharg
aliv
hospit
whichev
came
first
primari
analysi
done
intentiontotreat
itt
popul
safeti
analysi
done
patient
start
assign
treatment
trial
regist
clinicaltrialsgov
find
feb
march
patient
enrol
randomli
assign
treatment
group
remdesivir
placebo
one
patient
placebo
group
withdrew
randomis
includ
itt
popul
remdesivir
use
associ
differ
time
clinic
improv
hazard
ratio
ci
although
statist
signific
patient
receiv
remdesivir
numer
faster
time
clinic
improv
receiv
placebo
among
patient
symptom
durat
day
less
hazard
ratio
advers
event
report
remdesivir
recipi
versu
placebo
recipi
remdesivir
stop
earli
advers
event
patient
versu
four
patient
stop
placebo
earli
interpret
studi
adult
patient
admit
hospit
sever
remdesivir
associ
statist
signific
clinic
benefit
howev
numer
reduct
time
clinic
improv
treat
earlier
requir
confirm
larger
studi
ongo
pandem
sever
acut
respiratori
syndrom
coronaviru
infect
led
case
death
global
april
although
infect
selflimit
infect
adult
develop
sever
pneumonia
requir
treatment
supplement
oxygen
addit
progress
critic
ill
hypoxaem
respiratori
failur
acut
respiratori
distress
syndrom
multiorgan
failur
necessit
ventilatori
support
often
sever
week
least
half
patient
coronaviru
diseas
covid
requir
invas
mechan
ventil
die
hospit
associ
burden
healthcar
system
especi
intens
care
unit
overwhelm
sever
affect
countri
although
sever
approv
drug
investig
agent
shown
antivir
activ
vitro
present
antivir
therapi
proven
effect
treat
sever
ill
patient
multicentr
openlabel
randomis
control
trial
rct
hydroxychloroquin
involv
adult
admit
hospit
report
signific
effect
drug
acceler
viral
clearanc
rct
enrol
patient
within
day
symptom
onset
found
favipiravir
superior
arbidol
term
clinic
recoveri
rate
day
patient
mild
ill
arbidol
vs
favipiravir
critic
ill
vs
sever
ill
one
uncontrol
studi
five
patient
given
convalesc
plasma
suggest
possibl
benefit
although
patient
alreadi
detect
neutralis
antibodi
receipt
plasma
openlabel
rct
oral
lopinavirritonavir
found
signific
effect
primari
outcom
measur
time
clinic
improv
ment
evid
reduct
viral
rna
titr
compar
control
howev
perprotocol
analys
suggest
possibl
reduct
time
clinic
improv
differ
day
particularli
treat
within
day
symptom
onset
studi
lopinavirritonavir
drug
ongo
remdesivir
also
monophosphoramid
prodrug
adenosin
analogu
broad
antivir
spectrum
includ
filovirus
paramyxovirus
pneumovirus
coro
na
virus
vitro
remdesivir
inhibit
human
anim
coronavirus
test
date
includ
shown
antivir
clinic
effect
anim
model
middl
east
respiratori
syndrom
mer
cov
infect
lethal
murin
model
mer
remdesivir
superior
regimen
combin
interferon
beta
lopinavirritonavir
remdesivir
potent
inhi
bitor
replic
human
nasal
bron
chial
airway
epitheli
cell
nonleth
rhesu
macaqu
model
infect
earli
remdesivir
admin
istrat
shown
exert
signific
antivir
clinic
effect
reduc
pulmonari
infiltr
viru
titr
bronchoalveolar
lavag
vs
vehicl
intra
venou
remdesivir
studi
treatment
ebola
viru
diseas
adequ
toler
less
effect
sever
monoclon
antibodi
therapeut
use
basi
individu
compa
sionat
use
past
sever
month
patient
countri
case
studi
report
benefit
sever
ill
patient
howev
clinic
antivir
efficaci
remdesivir
remain
establish
report
result
placebocontrol
randomis
trial
remdesivir
patient
sever
investigatoriniti
individu
randomis
placebocontrol
doubleblind
trial
assess
effect
safeti
intraven
remdesivir
adult
age
year
admit
hospit
sever
trial
done
ten
hospit
wuhan
hubei
china
ethic
approv
obtain
institut
review
board
particip
hospit
written
inform
consent
obtain
patient
legal
repres
unabl
provid
consent
trial
done
accor
danc
principl
declar
helsinki
intern
confer
harmonizationgood
clinic
practic
guidelin
protocol
avail
abl
onlin
elig
patient
men
nonpregn
women
age
least
year
rtpcr
posit
pneumonia
evid
studi
search
pubm
april
publish
clinic
trial
assess
effect
remdesivir
among
patient
laboratoryconfirm
coronaviru
diseas
search
term
use
remdesivir
clinic
trial
random
control
trial
identifi
publish
clinic
trial
effect
remdesivir
patient
studi
first
randomis
doubleblind
placebocontrol
clinic
trial
assess
effect
intraven
remdesivir
adult
admit
hospit
sever
studi
termin
attain
prespecifi
sampl
size
intentiontotreat
popul
primari
endpoint
time
clinic
improv
significantli
differ
group
numer
shorter
remdesivir
group
control
group
particularli
treat
within
day
symptom
onset
durat
invas
mechan
ventil
although
also
significantli
differ
group
numer
shorter
remdesivir
recipi
placebo
recipi
statist
signific
benefit
observ
remdesivir
treatment
beyond
standard
care
treatment
trial
attain
predetermin
sampl
size
outbreak
brought
control
china
futur
studi
remdesivir
includ
earlier
treatment
patient
higherdos
regimen
combin
antivir
neutralis
antibodi
sever
need
better
understand
potenti
effect
trial
protocol
see
http
wwwresearchsquar
confirm
chest
imag
oxygen
satur
lower
room
air
ratio
arteri
oxygen
partial
pressur
fraction
inspir
oxygen
mm
hg
less
within
day
symptom
onset
elig
patient
childbear
age
men
women
agre
take
effect
contracept
measur
includ
hormon
contracept
barrier
method
abstin
studi
period
least
day
last
studi
drug
administr
exclus
criteria
includ
pregnanc
breast
feed
hepat
cirrhosi
alanin
aminotransferas
aspart
aminotransferas
five
time
upper
limit
normal
known
sever
renal
impair
estim
glomerular
filtrat
rate
mlmin
per
receipt
continu
renal
replac
therapi
haemodialysi
periton
dialysi
possibl
transfer
nonstudi
hospit
within
h
enrol
investig
treatment
studi
day
screen
use
treatment
includ
lopinavirritonavir
permit
elig
patient
randomli
assign
either
remdesivir
group
placebo
group
randomis
stratifi
accord
level
respiratori
support
follow
oxygen
support
oxygen
support
nasal
duct
mask
highflow
oxygen
noninvas
ventil
invas
ventil
extracorpor
membran
oxygen
permut
block
patient
per
block
randomis
sequenc
includ
stratif
prepar
statistician
involv
trial
use
sa
softwar
version
elig
patient
alloc
receiv
medic
individu
number
pack
accord
sequenti
order
randomis
centr
jin
yintan
hospit
central
pharmaci
envelop
prepar
emerg
unmask
patient
receiv
either
intraven
remdesivir
mg
day
follow
mg
day
singl
daili
infus
volum
placebo
infus
total
day
provid
gilead
scienc
foster
citi
ca
usa
patient
assess
daili
train
nurs
use
diari
card
captur
data
sixcategori
ordin
scale
safeti
day
death
clinic
data
record
use
whointern
sever
acut
respiratori
emerg
infect
consortium
isar
case
record
form
safeti
assess
includ
daili
monitor
advers
event
clinic
laboratori
test
day
electrocardiogram
day
daili
vital
sign
measur
clinic
data
record
paper
case
record
form
doubl
enter
electron
databas
valid
trial
staff
naso
pharyng
oropharyng
swab
expector
sputa
avail
faecal
anal
swab
specimen
collect
day
viral
rna
detect
quantif
trial
monitor
contract
research
organis
hangzhou
tigerm
consult
virolog
test
done
teddi
clinic
research
laboratori
tigermeddian
hangzhou
china
use
quantit
realtim
rtpcr
rna
extract
clinic
sampl
magna
pure
system
roch
rotkreuz
switzerland
detect
quantifi
coba
qpcr
roch
use
lightmix
modular
assay
tib
mobiol
berlin
germani
baselin
upper
nasopharyng
oropharyng
swab
lower
respiratori
tract
specimen
test
detect
egen
rnadepend
rna
polymeras
gene
ngene
sampl
subsequ
visit
quantit
qualit
assess
egen
primari
clinic
endpoint
time
clinic
improv
within
day
randomis
clinic
improv
defin
twopoint
reduct
patient
admiss
statu
sixpoint
ordin
scale
live
discharg
hospit
whichev
came
first
sixpoint
scale
follow
hospit
admiss
extracorpor
membran
oxygen
mechan
hospit
admiss
noninvas
ventil
highflow
oxygen
hospit
admiss
oxygen
therapi
requir
highflow
noninvas
ventil
hospit
admiss
requir
oxygen
discharg
reach
discharg
criteria
defin
clinic
recoveryi
normalis
pyrexia
respiratori
rate
breath
per
minut
satur
peripher
oxygen
room
air
relief
cough
maintain
least
h
sixpoint
scale
modifi
sevenpoint
scale
use
previou
lopinavirritonavir
rct
combin
two
outpati
strata
one
secondari
outcom
proport
patient
categori
sixpoint
scale
day
randomis
allcaus
mortal
day
frequenc
invas
mechan
ventil
durat
oxygen
therapi
durat
hospit
admi
sion
proport
patient
nosocomi
infect
virolog
measur
includ
proport
patient
viral
rna
detect
viral
rna
load
measur
quantit
rtpcr
safeti
outcom
includ
treatmentemerg
advers
event
seriou
advers
event
prematur
discontinu
studi
drug
origin
design
requir
total
event
across
group
would
provid
power
onesid
type
error
hazard
ratio
hr
compar
remdesivir
placebo
correspond
chang
time
clinic
improv
day
assum
time
clinic
improv
day
placebo
one
interim
analysi
use
triangular
boundari
alloc
ratio
remdesivir
placebo
account
origin
design
assum
event
rate
within
day
across
group
dropout
rate
impli
patient
recruit
trial
placebo
remdesivir
possibl
interim
analysi
enrol
patient
includ
design
request
independ
data
safeti
monitor
board
primari
efficaci
analysi
done
intentiontotreat
itt
basi
randomli
assign
patient
time
clinic
improv
assess
patient
reach
day
clinic
improv
day
death
day
consid
right
censor
day
time
clinic
improv
portray
kaplanmei
plot
compar
logrank
test
hr
ci
clinic
improv
hr
ci
clinic
deterior
calcul
cox
proport
hazard
model
analys
includ
subgroup
analys
receiv
treatment
day
less
vs
day
symptom
onset
time
clinic
deterior
defin
one
categori
increas
death
viral
rna
load
entri
differ
continu
variabl
group
calcul
use
hodgeslehmann
feb
march
patient
screen
elig
figur
patient
assign
receiv
remdesivir
receiv
placebo
one
patient
placebo
group
withdrew
previous
written
inform
consent
randomis
patient
includ
itt
popul
patient
enrol
march
control
outbreak
wuhan
basi
termin
criteria
specifi
protocol
data
safeti
monitor
board
recommend
studi
termin
data
analys
march
stage
interim
analysi
abandon
assumpt
stay
actual
enrol
particip
statist
power
reduc
three
patient
remdesivir
group
start
assign
treatment
includ
safeti
analys
figur
median
age
studi
patient
year
iqr
sex
distribut
men
versu
women
remdesivir
group
versu
placebo
group
tabl
common
comorbid
hypertens
follow
diabet
coronari
heart
diseas
lopinavirritonavir
coadminist
patient
baselin
patient
categori
sixpoint
ordin
scale
clinic
statu
baselin
imbal
exist
enrol
group
includ
patient
hypertens
diabet
coronari
arteri
diseas
remdesivir
group
placebo
group
patient
control
group
remdesivir
group
symptomat
day
less
time
start
remdesivir
placebo
treatment
higher
proport
remdesivir
recipi
respiratori
rate
breath
per
min
major
differ
symptom
sign
laboratori
result
diseas
sever
treatment
observ
group
baselin
median
time
symptom
onset
start
studi
treatment
day
iqr
import
differ
appar
group
treatment
receiv
includ
lopinavirrito
navir
corticosteroid
time
symptom
onset
corticosteroid
therapi
day
durat
corticosteroid
therapi
day
data
median
iqr
n
three
patient
start
treatment
includ
time
symptom
onset
start
studi
treatment
subgroup
analys
patient
use
remdesivir
within
day
symptom
onset
mortal
significantli
differ
group
although
numer
higher
placebo
group
contrast
group
patient
late
use
remdesivir
patient
numer
higher
mortal
although
signific
differ
clinic
improv
rate
day
day
also
significantli
differ
group
numer
higher
remdesivir
group
placebo
group
patient
assign
remdesivir
group
durat
invas
mechan
ventil
significantli
differ
numer
shorter
assign
control
group
howev
number
patient
invas
mechan
ventil
small
signific
differ
observ
two
group
length
oxygen
support
hospit
length
stay
day
randomis
discharg
day
randomis
death
distribut
sixcategori
scale
day
day
day
tabl
appendix
p
patient
remdesivir
group
placebo
group
rtpcr
posit
enrol
data
avail
undetec
tabl
viral
rna
nasopharyng
oropharyng
swab
taken
base
line
mean
baselin
viral
load
nasopharyng
oropharyng
swab
log
copi
per
ml
se
remdesivir
group
log
copi
per
ml
control
group
tabl
viral
load
decreas
time
similarli
group
figur
differ
viral
load
observ
stratifi
interv
symptom
onset
start
studi
treatment
appendix
p
subset
patient
expector
sputa
could
obtain
patient
mean
viral
rna
load
enrol
nearli
higher
remdesivir
group
placebo
group
enrol
figur
adjust
baselin
sputum
viral
load
enrol
remdesivir
group
show
signific
differ
day
placebo
slightli
rapid
declin
load
cumul
rate
undetect
viral
rna
nasopharyng
oropharyng
swab
day
patient
neg
proport
similar
among
patient
receiv
remdesivir
receiv
placebo
appendix
p
advers
event
report
patient
remdesivir
group
control
group
tabl
common
advers
event
remdesivir
group
constip
hypoalbuminaemia
hypokalaemia
anaemia
thrombocytopenia
increas
total
bilirubin
placebo
group
common
hypoalbuminaemia
constip
anaemia
hypokalaemia
increas
aspart
aminotransferas
increas
blood
lipid
increas
total
bilirubin
seriou
advers
event
report
remdesivir
group
report
control
group
patient
remdesivir
group
placebo
group
discontinu
studi
drug
advers
event
seriou
advers
event
remdesivir
group
vs
four
placebo
group
among
seven
due
respiratori
failur
acut
respiratori
distress
syndrom
remdesivir
group
death
observ
period
judg
site
investig
unrel
intervent
trial
found
intraven
remdesivir
significantli
improv
time
clinic
improv
mortal
time
clearanc
viru
patient
seriou
compar
placebo
compar
data
mean
se
result
less
lower
limit
quantif
pcr
assay
greater
limit
qualit
detect
imput
half
actual
valu
result
patient
viralneg
rna
imput
log
copi
per
ml
previou
studi
compassion
use
remdesivir
studi
popul
less
ill
eg
time
enrol
invas
mechan
ventil
extracorpor
membran
oxygen
vs
previou
studi
treat
somewhat
earlier
diseas
cours
median
day
vs
day
differ
might
expect
favour
remdesivir
provid
greater
effect
studi
popul
result
meet
expect
howev
studi
reach
target
enrol
stringent
public
health
measur
use
wuhan
led
mark
reduct
new
patient
present
midmarch
restrict
hospit
bed
avail
result
patient
enrol
later
cours
diseas
consequ
could
adequ
assess
whether
earlier
remdesivir
treatment
might
provid
clinic
benefit
howev
among
patient
treat
within
day
symptom
onset
remdesivir
signific
factor
associ
numer
reduct
day
median
time
clinic
improv
ongo
con
troll
clinic
trial
expect
confirm
refut
find
one
murin
model
sar
remdesivir
treatment
start
day
infect
viru
replic
lung
airway
epitheli
damag
alreadi
peak
significantli
reduc
lung
titr
decreas
diseas
sever
mortal
need
earli
treatment
found
nonhuman
primat
model
sar
mer
viru
replic
shortliv
lung
patholog
appear
develop
rapidli
human
infect
find
argu
test
remdesivir
earlier
remdesivir
result
signific
reduct
rna
load
detect
upper
respiratori
tract
sputum
specimen
studi
despit
show
strong
antivir
effect
preclin
model
infect
coronavirus
african
green
monkey
kidney
vero
cell
remdesivir
inhibit
effect
concentr
ec
ec
human
nasal
bronchial
airway
epitheli
cell
fix
concentr
reduc
estim
intracellular
viral
titr
log
tissu
cultur
infect
dose
per
ml
h
human
airway
epitheli
cell
ec
remdesivir
sarscov
merscov
murin
model
mer
subcutan
remdesivir
show
signific
antivir
clinic
effect
dose
regimen
maintain
plasma
concentr
greater
throughout
dose
interv
rhesu
macaqu
mgkg
dose
report
roughli
equival
daili
dose
human
effect
treatment
merscov
infect
reduc
pulmonari
viru
replic
start
h
infect
healthi
adult
volunt
receiv
dose
similar
trial
mg
day
mg
day
mean
peak
plasma
concentr
percentag
coeffici
variat
day
day
dose
mgday
day
adequ
toler
healthi
adult
daili
dose
regimen
mg
day
follow
mg
day
appear
gener
well
toler
one
patient
ebola
meningoenceph
howev
pharmacokinet
remdesivir
sever
ill
patient
particularli
concentr
activ
nucleotid
metabolit
triphosph
respiratori
tract
cell
treat
patient
unknown
studi
higherdos
regimen
safeti
data
eg
mg
daili
dose
warrant
consid
erat
sever
studi
found
remdesivir
adequ
toler
new
safeti
concern
identifi
overal
proport
patient
seriou
advers
event
tend
lower
remdesivir
recipi
placebo
recipi
howev
higher
proport
remdesivir
recipi
placebo
recipi
dose
prematur
stop
investig
advers
event
includ
gastrointestin
symptom
anorexia
nausea
vomit
aminotransferas
bilirubin
increas
worsen
cardiopulmonari
statu
limit
studi
includ
insuffici
power
detect
assum
differ
clinic
outcom
initi
treatment
quit
late
absenc
data
infecti
viru
recoveri
possibl
emerg
reduc
suscept
remdesivir
note
nonhuman
primat
inhibitori
effect
remdesivir
infecti
recoveri
bronchoalveolar
lavag
much
greater
control
viral
rna
detect
upper
lower
respiratori
tract
specimen
consist
de
creas
versu
control
coronavirus
partial
resist
inhibit
remdesivir
sixtim
increas
ec
obtain
serial
vitro
passag
virus
remain
suscept
higher
remdesivir
concentr
show
impair
fit
frequent
use
corticosteroid
patient
group
might
promot
viral
replic
observ
sar
mer
although
studi
report
pro
longat
detect
viral
rna
infecti
viru
furthermor
answer
whether
longer
treatment
cours
higher
dose
remdesivir
would
benefici
patient
sever
summari
found
dose
regimen
intraven
remdesivir
adequ
toler
provid
signific
clinic
antivir
effect
serious
ill
patient
howev
could
exclud
clinic
meaning
differ
saw
numer
reduct
clinic
paramet
ongo
studi
larger
sampl
size
continu
inform
understand
effect
remdesivir
furthermor
strategi
enhanc
antivir
potenc
remdesivir
eg
higherdos
regimen
combin
antivir
neutralis
antibodi
mitig
immuno
patholog
host
respons
contribut
sever
eg
inhibitor
requir
rigor
studi
patient
sever
bc
cw
yew
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
cw
bc
decid
publish
paper
bc
cw
yew
pwh
tj
fgh
provid
input
trial
design
bc
cw
yew
fgh
pwh
respons
acquisit
analysi
interpret
data
yew
fgh
pwh
gf
draft
manuscript
bc
cw
pwh
fgh
gf
tj
xg
critic
revis
manuscript
yew
contribut
statist
analysi
gf
gave
valuabl
suggest
data
analysi
author
contribut
conduct
trial
fgh
serv
noncompens
consult
gilead
scienc
respiratori
antivir
programm
outsid
submit
work
author
declar
compet
interest
approv
human
genet
resourc
administr
china
trial
data
share
qualifi
research
submit
propos
valuabl
research
question
contract
sign
